<DOC>
	<DOCNO>NCT00443950</DOCNO>
	<brief_summary>The objective study compare Chinese subject rheumatoid arthritis ( RA ) efficacy safety subject population 50 mg once-weekly injection etanercept versus placebo subject receive methotrexate . This multi-center , double-blind , randomize , parallel placebo-controlled outpatient study . Approximately 150 subject participate study 18 week include screen period 4 week , 12-week treatment period , 2-week follow-up period approximately 25 site .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Etanercept Chinese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Must Chinese ancestry live China . Meets American Rheumatism Association 1987 Revised Criteria Classification RA . Have active RA time study enrollment ( start screening period , ) demonstrate 5 swollen 5 tender/painful joint . Previous receipt etanercept ; antibody tumor necrosis factor ( TNF ) antibody ( infliximab , adalimumab ) , antiCD4 antibody diphtheria IL2 fusion protein ( DAB IL2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Chinese</keyword>
</DOC>